Back HIV/AIDS HIV/AIDS Topics HIV Treatment

IAS 2013: Cost of HIV Drugs in Resource-limited Settings [VIDEO]

The price of first- and second-line antiretroviral medications has fallen in recent years, largely due to increased competition among generic drug producers, but the newest antiretrovirals continue to be priced out of reach of many who need them, according to a report released by Médecins Sans Frontières/Doctors Without Borders to coincide with the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

Read more:

IAS 2013: Stribild 'Quad' Pill Continues to Show Good Efficacy at 96 Weeks

The 4-in-1 Stribild single-tablet regimen maintains HIV viral load suppression through 96 weeks and remains generally well-tolerated, researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur. Another study found that Stribild and its component cobicistat appear safe for people with mild-to-moderate kidney impairment.

alt

Read more:

HIV+ Boy Dies After HIV-resistant Stem Cell Transplant for Leukemia

A 12-year-old HIV positive boy with acute lymphoblastic leukemia died earlier this month due to graft-versus-host disease complications after undergoing an experimental cord blood transplant in April from a donor with the CCR5-delta-32 (CCR5-Δ-32) mutation, which makes cells resistant to HIV entry, the University of Minnesota announced this week.

alt

Read more:

IAS 2013: Meta-analysis Finds Early HIV Treatment Reduces Risk of AIDS and Death

A meta-analysis of more than 30 studies found that starting antiretroviral therapy with a CD4 T-cell count above 350 cell/mm3 was associated with a lower risk of progression to AIDS or death, according to a poster presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur.

alt

Read more:

IAS 2013: The Future of HIV Cure Research [VIDEO]

Research towards a cure for HIV was a key theme of the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) last month in Kuala Lumpur, as well as a 2-day IAS pre-conference. While hesitant to make firm predictions, experts offered some cautious opinions on the future of cure research.

alt

Read more:

IAS 2013: Intensive ART During Primary HIV Infection Lowers Viral Reservoir

Starting intensive antiretroviral therapy (ART) with a 5-drug regimen during the earliest stages of HIV infection can result in lower levels of virus in resting T-cell reservoirs, leading to improved immune function and potentially a better chance at a functional cure, according to studies presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur.

alt

Read more:

IAS 2013: Darunavir/Ritonavir Is Safe and Effective for Younger Children with HIV

Over 80% of treatment-experienced children with HIV aged 3 to 6 years who received ritonavir-boosted darunavir (Prezista) with an optimized background regimen achieved virological suppression by 48 weeks, with a favorable safety profile, according to a report at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur.

alt

Read more: